Facebook's (FB) CEO Mark Zuckerberg on Q4 2014 Results

Earnings Call ... - 10 hours ago
As Mark said, video grew...

VIDEO: BiOasis Technologies: Therapeutic Drug Delivery Platform for Central ...

Midas Letter - 17 hours ago
We'd be able to look at...

Cegedim Relationship Management stellt neue Version der weltweiten ...

SYS-CON Media (press release) - 16 hours ago
Neben CRM-Lösungen stellt Cegedim...

Merck wählt CRedit360 für konsistentes Management globaler ...

SYS-CON Media (press release) - 4 hours ago
... Novo Nordisk, Deutsche Bank,...

Frog-Angebot von Wyplay erfüllt die Kriterien von Frost & Sullivan für die ...

SYS-CON Media (press release) - 5 hours ago
Frost & Sullivan schreibt...

Klondex Increases Mineral Resource Estimate at Fire Creek

SYS-CON Media (press release) - 3 hours ago
Drill and channel assays were...

Benu Networks gibt Einstieg von Shaw Ventures als strategischer Investor bekannt

SYS-CON Media (press release) - 2 days ago
„Dank dieser Finanzierungsrunde...

8 who wrote Obama letters to attend State of Union

WPXI Pittsburgh - 1 week ago
In this photo taken Oct. 27, 2013,...

Notable Gifts: Anthem invests in expanded diabetes education efforts

Richmond.com - 2 weeks ago
The Julius Rosenwald High School...

Kroll Ontrack voorspelt voor 2015 drastische veranderingen in de e ...

SYS-CON Media (press release) - 2 days ago
De trend om e-discovery uit te...

News via Google. See more news matching 'als expanded access'

 

Expanded Access

Bringing Research and Patients Together

Our Expanded Access platform is meant to do two things:

  1. Empower patients with access to new treatments that are in clinical research.
  2. Empower further research with clinical data from those patients.

For someone with a quick-killer disease, participating in clinical research may be the only way to access a new medicine that might help him live longer.  He may be willing to accept some uncertainty, considering the alternative.  So for patients, there’s a lot of overlap between treatment exploration and research.

But what about patients who cannot get into clinical trials?  Can they still take part in research and explore investigational treatment?

Yes, they can, but only through what are called Expanded Access programs (EAPs).  These are meant to include a much broader group of patients than traditional clinical trials, sometimes exclusively those patients who don’t meet clinical trial enrollment criteria or who otherwise cannot get into trials.

ALS-ETF is bringing a new kind of Expanded Access to the ALS community, to make a groundbreaking impact in the treatment landscape for patients as well as the research that’s powered by patient data.

Learn more about Expanded Access programs here.

Learn more about our research goals here.